Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study

Our aim was to investigate the efficacy and safety of initial neoadjuvant endocrine therapy with exemestane alone followed by tailored treatment, either continued exemestane monotherapy or exemestane plus docetaxel–cyclophosphamide (TC) combination therapy, in postmenopausal patients with primary in...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cancer Med
Main Authors: Sato, Nobuaki, Masuda, Norikazu, Morimoto, Takashi, Ueno, Takayuki, Kanbayashi, Chizuko, Kaneko, Koji, Yasojima, Hiroyuki, Saji, Shigehira, Sasano, Hironobu, Morita, Satoshi, Ohno, Shinji, Toi, Masakazu
פורמט: Artigo
שפה:Inglês
יצא לאור: John Wiley and Sons Inc. 2019
נושאים:
Clinical Cancer Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6745863/
https://ncbi.nlm.nih.gov/pubmed/31361400
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2423
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים